Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
- 84 Downloads
This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.
Patients with ovarian carcinoma treated at our hospital between 2000 and 2017 were identified. The risk factors of TEEs, including venous TEEs and arterial TEEs, and the association between TEEs and prognosis were investigated. Patients with TEEs were classified into two groups: those with severe TEEs, defined as patients who required urgent treatment for deep vein thrombosis, massive pulmonary embolism, acute myocardial infarction, and symptomatic cerebral infarction, and those with mild TEEs. The risk factors of severe TEEs and the association between severe TEEs and prognosis were investigated.
A total of 369 patients were enrolled. Among them, 53 patients (14.4%) were complicated with TEEs. Clear cell carcinoma (CCC) was a greater risk factor of TEEs than serous carcinoma (hazard ratio [HR] = 2.81, p = 0.03). In multivariate analysis for survival, TEEs were a prognostic factor of poor progression-free survival (PFS; HR = 2.90, p < 0.01) and overall survival (OS; HR = 2.89, p < 0.01). Among 53 patients with TEEs, 17 (32.1%) developed severe TEEs. CCC was strongly associated with severe TEEs (HR = 42.6, p = 0.02). Multivariate analysis for survival demonstrated that severe TEEs were a risk factor of worse PFS (HR = 4.34, p < 0.01) and OS (HR = 3.30, p = 0.03).
TEEs induced poor prognosis and was associated with CCC. A standard treatment for CCC should be included in the strategy of TEEs.
KeywordsOvarian cancer Thromboembolic events Venous thromboembolism Arterial thromboembolism Clear cell carcinoma
Compliance with ethical standards
Conflicts of interest
All authors declare no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Informed consent was not obtained because our study was a retrospective analysis.
- 2.Burgers A, Schmalfeldt B (2011) Ovarian cancer diagnosis and treatment. Dtsch Arztebl Int 108:635–641Google Scholar
- 3.Pujade-Lauraine E, Alexander J (2011) Update of randomized trials in recurrent disease. Ann Oncol Suppl 8:61–64Google Scholar
- 14.Ye S, Yang J, Cao D et al (2015) Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study. PLoS ONE 10:1–10Google Scholar
- 27.Koizume S, Miyagi Y (2015) Tissue factor-factor VII complex as a key regulator of ovarian cancer phenotypes. Biomarker Cancer 7:1–13Google Scholar
- 31.Yoshikawa T, Miyamoto M, Aoyama T et al (2018) JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett 15:5772–5780Google Scholar